24316 Federal Register / Vol. 72, No. 84 / Wednesday, May 2, 2007 / Notices 

Dated: April 19, 2007. 

Daniel C. Schneider, 

Acting Assistant Secretary for Children and 

Families. 

[FR Doc. E7–8318 Filed 5–1–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Statement of Organization, Functions 

and Delegation of Authority 

Notice is hereby given that I have 

delegated to the Principal Deputy 

Assistant Secretary, Deputy Assistant 

Secretaries, Program Directors, Program 

Commissioners, Deputy Director/ 

Commissioner, Office of Child Support 

Enforcement, and Staff Office Directors 

the following authority vested in me by 

the Secretary of Health and Human 

Services in the memorandum dated 

August 20, 1991, Delegations of 

Authority for Social Security Act 

Programs; 31 U.S.C. 1535; and HHS 

General Administrative Manual, 

Chapter 8–77. 

(a) Authorities Delegated. 

1. Authority to administer approved 

cooperative research experimental, pilot 

or demonstration projects under the 

provisions of sections 1110 and 1115 of 

the Social Security Act. 

2. Authority to approve interagency 

agreements to procure, provide or 

exchange services, supplies or 

equipment. 

(b) Limitations. 

1. The authority listed in ι1 above 

shall be exercised under the condition 

that projects may be administered by the 

Office of Planning, Research and 

Evaluation (OPRE), by the program/staff 

office or jointly by OPRE with the 

program/staff office. 

2. Where all or any part of an 

experimental, pilot, research or 

demonstration project is wholly 

financed with Federal funds made 

available under sections 455(e), 1110 or 

1115 of the Social Security Act, without 

any State, local or other non-Federal 

financial participation, that project must 

be approved by the Secretary of Health 

and Human Services. 

3. This delegation of authority does 

not include the authority to approve/ 

disapprove projects under sections 1110 

or 1115 of the Social Security Act or 

approve/disapprove waivers of State 

Plan requirements or costs that would 

not otherwise be included as 

expenditures under the provisions of 

section 1115(a)(1) and (2) of the Social 

Security Act. 

4. The authority to approve 

interagency agreements to procure, 

provide, or exchange services, supplies, 

or equipment requires the concurrence 

of the ACF Chief Financial Officer if it 

exceeds $250,000 (including 

amendments) within a fiscal year or if 

it requires the signature of the Assistant 

Secretary, ACF, or the Secretary of HHS. 

(c) Effect on Existing Delegations. 

As related to this delegation of 

authority, this delegation supersedes all 

previous delegations of authority 

involving the administration of the 

cross-program authorities delegated 

herein. 

(d) Effective Date. 

This delegation is effective upon the 

date of signature. 

I hereby ratify and affirm any actions 

taken by the Principal Deputy Assistant 

Secretary, Deputy Assistant Secretaries, 

Program Directors, Program 

Commissioners, Deputy Director/ 

Commissioner, Office of Child Support 

Enforcement, and Staff Office Directors, 

which involved the exercise of the 

authority delegated herein prior to the 

effective date of this delegation. 

Dated: April 19, 2007. 

Daniel C. Schneider, 

Acting Assistant Secretary for Children and 

Families. 

[FR Doc. E7–8319 Filed 5–1–07; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2007D–0135] 

Guidance for Industry on Testing of 

Glycerin for Diethylene Glycol; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

availability of a guidance for industry 

entitled ‘‘Testing of Glycerin for 

Diethylene Glycol.’’ This guidance 

provides recommendations on testing 

that will help pharmaceutical 

manufacturers, repackers, and other 

suppliers of glycerin, and pharmacists 

who engage in drug compounding, 

avoid the use of glycerin that is 

contaminated with diethylene glycol 

(DEG) and prevent incidents of DEG 

poisoning. 

DATES: Submit written or electronic 

comments on the guidance by July 31, 

2007. General comments on agency 

guidance documents are welcome at any 

time. 

ADDRESSES: Submit written requests for 

single copies of the guidance to the 

Division of Drug Information (HFD– 

240), Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857. Send one selfaddressed adhesive label to assist that 

office in processing your requests. 

Submit written comments on the 

guidance to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.fda.gov/dockets/ecomments. See 

the SUPPLEMENTARY INFORMATION section 

for electronic access to the guidance 

document. 

FOR FURTHER INFORMATION CONTACT: 

Monica Caphart, Center for Drug 

Evaluation and Research (HFD–320), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857,301– 

827–9047. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

a guidance for industry entitled 

‘‘Testing of Glycerin for Diethylene 

Glycol.’’ This guidance explains that the 

agency recommends that certain 

analytical testing procedures be 

performed on glycerin to avoid the use 

of DEG-contaminated product. 

Specifically, the agency is 

recommending that all lots of glycerin 

received by a pharmaceutical 

manufacturing facility undergo identity 

testing that includes a test for DEG 

content. DEG contamination of glycerin 

can be detected by using specific 

analytical test procedures described in 

the United States Pharmacopeia 

monograph for glycerin, which 

quantifies the amount of DEG present at 

a detection level of 0.1 percent, as 

recommended by the interagency 

Diethylene Glycol Contamination 

Prevention Workshop of 1997. 

Repackers, pharmacy compounders, and 

others who distribute and prepare 

glycerin for use in drug products should 

test glycerin that is used, sold for use, 

or intended for use in drug products. 

This recommendation also applies to 

bulk or repackaged glycerin intended as 

an excipient or other component for a 

drug. In addition, pharmacies that 

purchase glycerin for use in 

compounding drug products should 

either test the glycerin or ensure that 

such testing was properly done by a 

reliable supplier. 

mmaher on DSK3CLS3C1PROD with $$_JOB